Iambic Therapeutics (IAM) Stock Price, News & Analysis

Company Overview

Iambic Therapeutics, Inc. (NASDAQ: IAM) is a clinical-stage biotechnology company focused on discovering and developing novel medicines, with an emphasis on small-molecule therapies. The company combines artificial intelligence, computational modeling and experimental drug discovery methods to identify potential drug candidates and accelerate the development process.

Iambic’s technology platform is designed to support multiple stages of pharmaceutical research, including target evaluation, molecule design, compound testing and optimization. Its pipeline is focused on potential treatments for serious diseases, although specific programs and development stages may change as the company advances its research and clinical activities.

The company was founded to apply modern computational technologies to drug discovery and is headquartered in the United States. Iambic Therapeutics primarily operates in the biotechnology and pharmaceutical research sector, serving patients and healthcare markets through the development of internally discovered therapeutic candidates. Publicly available information about its commercial products and international operations remains limited.

Key Stats

• Today's Range: $19.31 to $25.00
• 50-Day Range: N/A
• 52-Week Range: $16.15 to $25.00
• Volume: 2.96 million shs
• Average Volume: N/A
• Market Capitalization: $162.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IAM
• CIK: 1997038
• Web: www.iambic.ai
• Phone: (626) 592-2520
• Fax: N/A
• Employees: 171
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $18.25 million
• Price / Sales: 8.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 6,810,000
• Free Float: N/A
• Market Cap: $162.15 million
• Optionable: N/A
• Beta: N/A